Toronto Innovation Acceleration Partners (TIAP) – formerly known as MaRS Innovation- and Amgen are collaborating to jointly fund emerging technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations will identify promising medical research conducted by the scientific community of Toronto and will further determine which ones have the potential to disrupt the medical industry. Rafi Hofstein, CEO of TIAP, expects that with Amgen’s philosophical and financial backing, the organization will be able to promote science and innovation reach its potential in the marketplace. Moreover, the joint venture will enrich TIAP’s presence in Canada as well as open up a meaningful dialogue with all stakeholders in the local health care system.

Reference Link: https://www.biospace.com/article/toronto-innovation-acceleration-partners-announces-strategic-partnership-with-amgen/

3 thoughts on “TIAP partners with Amgen to commercialize medical research”

Leave a Reply

Your email address will not be published.